Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
December 27, 2004
- List of Institutions Which Received Delivery of MPC's Fibrinogen Preparations Published
December 27, 2004
- JSGM to Introduce GE Information System on Full Scale in April
December 27, 2004
- REGULATORY NEWS IN BRIEF
December 27, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 27, 2004
- NEW PRODUCTS
December 27, 2004
- Website News
December 27, 2004
- Base Sequences Predict Iressa Adverse Reactions: IMSUT Group
December 27, 2004
- Fujirebio, SRL to Consolidate in April 2005
December 27, 2004
- 2004 Spot Test Market Totals \94.4 Bil. in 2003: Fuji-keizai
December 27, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 27, 2004
- Astellas Pharma to Explore Any Possibility to Become a Global Mega Pharma
December 27, 2004
- Norvasc Ranked at Top in 3rd Qtr: IMS Data
December 27, 2004
- Sanofi-Synthelabo, Aventis Pharma to Consolidate Their Businesses in January 2005
December 27, 2004
- Kaken to Make Trafermin Blockbuster by Add. Indication, Formulation
December 27, 2004
- Taisho Starts PI Trials for Antidepressant TS-041
December 27, 2004
- Non-wholesale Business to Account for 50% of Ordinary Profits in 2010: Suzuken
December 27, 2004
- LTT to Start PIIa Trial on PC-SOD in Japan
December 27, 2004
- Wholesalers' Distribution Cost Ratio Higher for Pharmacies: FJPWA Survey
December 27, 2004
- NEW PRODUCTS
December 20, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…